Bioethics Education International (BEI) advances policy and intercultural bioethics debates from the beginning to the end of life.
Who We Are
BEI is a 501c3 tax exempt not-for-profit international organization incorporated in the State of New York, located in Manhattan.
Who will benefit from BEI’s programs and activities?
The organization benefits students, professionals and policy makers from various fields, such as healthcare, the humanities, and the law, as well as policy makers and the public at large. It aims to provide stakeholders with resources to understand and find solutions to issues in global health, health care, new medical technologies, and the life sciences.
How will BEI achieve its educational and outreach purposes?
Through an online bioethics hub, BEI is offering engaging and interactive e-learning courses, webinars, and training sessions. The hub will offer timely topics in bioethics in creative ways, incorporating an interdisciplinary and intercultural approach to confronting ethical issues in medicine, bioscience, medical technology, life sciences, and the environment. BEI provides public access to international bioethics education, facilitates collaborative learning, networking and community debates across the life course around the globe.
News and Articles
Controversial Infant Vaccine Study in Guinea Bissau Will Proceed, Officials Say
A controversial hepatitis B vaccine trial in Guinea‑Bissau, planned to enroll 14,000 newborns, is reportedly proceeding according to U.S. officials, despite ethical concerns and reports of its cancellation. The five-year trial, funded by a $1.6 million CDC [...]
Bioethics Education International Winter School Online 2023 – Testimonials
Bioethics Education International (BEI) invited participants (students and professionals) across the globe to attend the summer school held from July 24 to 29, 2023. The summer school included lectures and seminars, film screenings, and special [...]
Baby Saved By Gene-Editing Therapy Takes 1st Steps Ahead Of Christmas
KJ was born last year with a genetic disorder called carbamoyl-phosphate synthetase 1 deficiency. When he was 6 months old, doctors began giving KJ a groundbreaking new treatment -- a personalized CRISPR gene editing therapy at Children's [...]